close

Anmelden

Neues Passwort anfordern?

Anmeldung mit OpenID

For more information, click here

EinbettenHerunterladen
An ESC Update Programme
Davos, Switzerland, 8–12 February 2015
Second Announcement
1
21st International Postgraduate Course on Cardiovascular Disease
University Hospital
Zurich
German Cardiac Society
Programme Directors
Thomas F. Lüscher, Zurich, Switzerland
Bertram Pitt, Ann Arbor MI, USA
Scientific Coordinator
Ruth Amstein, Zurich, Switzerland
In collaboration with
Ne
u
Arterielle Hypertonie
P E R I N D O P R I L A R G I N I N + A M L O D I P I N + I N D A PA M I D
Referenzen: * Bei Typ 2-Diabetikern. 1. Chalmers J et al., Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the
Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial. Hypertension, 2014;63:259-264. Coveram® Plus. Z: Filmtabletten Coveram® Plus 5 mg/5 mg/
1.25 mg mit 5 mg Perindopril-Arginin, 5 mg A mlodipin und 1.25 mg Indapamid; Coveram® Plus 5 mg/10 mg/1.25 mg; Coveram® Plus 10 mg/5 mg/2.5 mg; Coveram® Plus 10 mg/10 mg/2.5 mg. I: Als
Substitutionstherapie zur Behandlung der essentiellen arteriellen Hypertonie bei Patienten, deren Blutdruck mit gleichzeitig in denselben Dosierungen eingenommenem Perindopril/Indapamid als
Kombinationspräparat und Amlodipin bereits eingestellt ist. D: Eine Tablette pro Tag, vorzugsweise morgens und vor einer Mahlzeit. Wenn eine Dosierungsänderung erforderlich ist, kann die Dosis von
Coveram® Plus modifiziert oder eine individuelle Anpassung der freien Kombination in Betracht gezogen werden. KI: Dialysepatienten. Patienten mit unbehandelter, dekompensierter Herzinsuffizienz. Schwere
Niereninsuffizienz (KreaClear <30 ml/min). Moderate Niereninsuffizienz (KreaClear 30-60 ml/min) für Coveram® Plus 10 mg/5 mg/2.5 mg und Coveram® Plus 10 mg/10 mg/2.5 mg. Gleichzeitige Anwendung
von Aliskiren bei Patienten, die an Diabetes (Typ 1 oder 2) oder an Niereninsuffizienz (KreaClear < 60 ml/min) leiden. Überempfindlichkeit gegenüber den Wirkstoffen oder anderen ACE-Hemmern, anderen
Dihydropyridin-Derivaten, anderen Sulfonamiden oder den Hilfsstoffen. Angioödem (Quincke-Ödem) in der Anamnese im Zusammenhang mit einer vorausgegangenen ACE-Hemmertherapie. Hereditäres oder
idiopathisches Angioödem. Schwangerschaft und Stillzeit. Hepatische Enzephalopathie. Schwere Leberinsuffizienz. Hypokaliämie. Kombination mit nicht-antiarrhythmischen Medikamenten, unter denen es zu
Torsades de pointes kommen kann. Schwere Hypotonie. Schock, einschliesslich kardiogenes Schock. Obstruktion des linksventrikulären Ausflusstrakts. Hämodynamisch instabile Herzinsuffizienz nach einem
akutem Myokardinfarkt. vM: Besondere Warnhinweise: Lithium. Neutropenie/Agranulozytose. Überempfindlichkeit/Angioödem. Anaphylaktische Reaktion während der Desensibilisierung. Anaphylaktische
Reaktionen während der Low-Density-Lipoprotein-Apherese (LDL-Apherese). Hämodialyse-Patienten. Kaliumsparende Diuretika, Kaliumsalze. Schwangerschaft. Doppelte Blockade des Renin-AngiotensinAldosteron-Systems (RAAS). Hepatische Enzephalopathie. Photosensibilität. Vorsichtsmassnahmen: Nierenfunktion. Hypotonie und Wasser- und Natriummangel. Kaliumblutspiegel. Kalziumblutspiegel.
Renovaskuläre Hypertonie. Husten. Atherosklerose. Hypertensive Krise. Herzinsuffizienz. Aorta- und Mitralklappenstenose/hypertrophe Kardiomyopathie. Ethnische Unterschiede. Chirurgischer
Eingriff/Anästhesie. Leberinsuffizienz. Harnsäure. Ältere Patienten. Ia: Lithium, Aliskiren bei anderen Patienten als jenen mit Diabetes oder mit schwerer Niereninsuffizienz, kaliumsparende Diuretika,
Kaliumsalze, Dantrolen (Infusion), Grapefruit oder Grapefruitsaft, Baclofen, NSAR (einschliesslich hochdosierte Acetylsalicylsäure), Antidiabetika, Torsades de pointes induzierende Arzneimittel,
Amphotericin B, Gluko- und Mineralokortikoide (systemisch), Tetracosactid, stimulierende Laxantien, herzwirksame Glykoside, CYP3A4-Induktoren, CYP3A4-Inhibitoren, Antidepressiva vom
Imipramin-Typ, Neuroleptika, andere Antihypertensiva und Vasodilatatoren, Kortikoide, Tetracosactid, Allopurinol, zytostatische oder immunsuppressive Wirkstoffe, Kortikosteroide (systemisch)
oder Procainamid, Anästhetika, Diuretika (Thiazid- oder Schleifendiuretika), Gold, Metformin, iodhaltige Kontrastmittel, Kalziumsalze, Ciclosporin.
uaW: Schwindelgefühl, Kopfschmerzen, Parästhesie, Vertigo, Schläfrigkeit, Sehstörungen, Tinnitus, Palpitationen, Flush, Hypotonie (und damit
verbundene Wirkungen), Husten, Dyspnoe, abdominale Sschmerzen, Anorexie, Verstopfung, Durchfall, Geschmacksstörungen, Dyspepsie, Übelkeit,
Erbrechen, Mundtrockenheit, Pruritus, Hautausschlag, makulopapulöser Ausschlag, makulopapulöse Eruption, Muskelkrämpfe, Knöchelschwellungen,
Asthenie, Müdigkeit, Ödem. P: Packung mit 30 und 60 Tabletten Coveram® Plus 5 mg/5 mg/1.25 mg, 5 mg/10 mg/1.25 mg, 10 mg/5 mg/2.5 mg
et 10 mg/10 mg/2.5 mg. Kassenzulässig, [B]. Für weitere Informationen vgl. www.swissmedicinfo.ch. Vertrieb Servier (Suisse) S.A., Satigny.
Table of Contents
Page
Welcome Address
4
Committees of Cardiology Update
5
Programme Overview
7
Teaching Faculty
8
Satellite Symposia
9
Special Sessions
10
Accreditation10
General Information
11
Travel Information
12
About the Zurich Heart House
13
Registration, Organisation
14
Sponsors16
Under the Auspices of
Foundation for Cardiovascular Research
European Society of Cardiology
3
In collaboration with
Welcome Address
Dear Colleagues
We are pleased to announce the 21st Cardiology Update Course, taking place in Davos,
Switzerland from 8-12 February 2015. This four-day programme will offer a comprehensive
update of major topics in cardiology, presented by a distinguished international teaching faculty.
Since its foundation in 1975, Cardiology Update has been held every second year in Davos, and
the course has benefited from a growing reputation and increasing number of participants over
the years. The course is a joint educational programme of the Zurich Heart House/Foundation for
Cardiovascular Research, the University Hospital Zurich, and the European Society of Cardiology
(ESC).
The educational objectives are to review and disseminate recent advances in the prevention,
diagnosis, and treatment of cardiovascular disease, as well as to discuss their impact on clinical
practice. Completing this course will enable attendees to treat patients in accordance with
current clinical evidence over the broad spectrum of cardiovascular disease, including
atherosclerosis and its risk factors, coronary artery disease, acute coronary syndromes,
arrhythmias, valve disease and heart failure. Special lectures and updates will be dedicated to
the new ESC Practice Guidelines to support physicians in clinical decision-making.
Cardiology Update is designed for clinicians specialised in cardiology, internal and general medicine. Aside from traditional state-of-the-art lectures, a strong emphasis is placed on
interactive education, aiming to provide guidance in everyday practice. The features include
case presentations with computer-assisted voting, clinical-decision-seminars and meet-theexpert-sessions. Moderated poster sessions will provide an opportunity for young researchers
to present their new scientific findings and interact with experts. The spirit of the course is
a stimulating working and learning environment, offering great opportunities for networking
among faculty members and participants.
4
We are looking forward to welcoming you at the next Cardiology Update meeting in 2015.
Thomas F. Lüscher, M.D.
Professor and Chairman Cardiology
University Hospital Zurich
Switzerland
Bertram Pitt, M.D.
Professor of Medicine Emeritus
University of Michigan School of Medicine
Ann Arbor MI, USA
Thierry C. Gillebert, M.D.
Professor of Cardiology
ESC Education Committee
University of Ghent
Belgium
Ruth Amstein, Ph.D.
Director Zurich Heart House
Foundation for Cardiovascular Research
Switzerland
Committees of Cardiology Update
5
Programme Committee
Ruth Amstein, Ph.D., Zurich, CH
Jeroen J. Bax, M.D., Leiden, NL
Paolo G. Camici, M.D., Milan, IT
Filippo Crea, M.D., Rome, IT
Volkmar Falk, M.D., Berlin, DE
Thierry C. Gillebert, M.D., Ghent, BE
Peter Libby, M.D., Boston MA, USA
Thomas F. Lüscher, M.D., Zurich, CH
Bernhard Meier, M.D., Berne, CH
Marc A. Pfeffer, M.D., Boston MA, USA
Fausto Pinto, M.D., Lisbon, PT
Bertram Pitt, M.D., Ann Arbor, MI, USA
Otto Smiseth, M.D., Oslo, NO
Karl Swedberg, M.D., Gothenburg, SE
Alec Vahanian, M.D., Paris, FR
Panos Vardas, M.D., Heraklion, GR
William Wijns, M.D., Aalst, BE
Stephan Windecker, M.D., Berne, CH
Salim Yusuf, Hamilton, Ontario, CA
Local Programme Committee Zurich
Ronald Binder, M.D.
Corinna Brunckhorst, M.D.
Firat Duru, M.D.
Frank Enseleit, M.D.
Andreas Flammer, M.D.
Michelle Frank, M.D.
Oliver Gämperli, M.D.
Matthias Greutmann, M.D.
Christiane Gruner, M.D.
Laurent Haegeli, M.D.
Roland Klingenberg, M.D.
Ulf Landmesser, M.D.
Robert Manka, M.D.
Willibald Maier, M.D.
Francesco Maisano, M.D.
Christian Matter, M.D.
Fabian Nietlispach, M.D.
Frank Ruschitzka, M.D.
Christian Schmied, M.D.
Jan Steffel, M.D.
Isabella Sudano, M.D.
Felix C. Tanner, M.D.
Christian Templin, M.D.
Silvia Ulrich, M.D.
Xarelto
®
Einfach besser
Einmal täglich 1 Tablette
Erste 3 Wochen zur Behandlung der TVT und LE 15mg 2x täglich
In 5 Indikationen besser als bisheriger Therapiestandard*
,1–5
Der erste ORALE, direkte Faktor-Xa-Inhibitor
TVT = tiefe Venenthrombose; LE = Lungenembolie.
* Bessere Wirksamkeit oder besserer klinischer Nettonutzen als bisheriger Antikoagulationsstandard
Gekürzte Fachinformation Xarelto® (Rivaroxaban): Direkter Faktor Xa-Inhibitor Z: Filmtabl. zu 10, 15 und 20 mg Rivaroxaban. I: a) Thromboseprophylaxe bei grösseren orthopädischen Eingriffen a. d. unteren Extremitäten wie Hüft- und Knieprothesen. b) Behandlung von Lungenembolie (LE) und tiefer Venenthrombose (TVT) sowie Prophylaxe rezidivierender TVT und LE. c) Schlaganfallprophylaxe und Prophylaxe system. Embolien bei nicht-valvulärem Vorhofflimmern. D: a) 1x/Tag 10 mg. b) 2x/Tag 15 mg für die ersten 21 Tage, gefolgt
von 20 mg 1x/Tag c) 1x/Tag 20 mg; bei Krea-Cl 15–49 ml/min: 1x/Tag 15 mg. 15 mg und 20 mg während Mahlzeit einnehmen. KI: Überempfindlichkeit auf Inhaltsstoffe, akute bakt.
Endokarditis, klin. sign. aktive Blutungen, schw. Lebererkrankung/Leberinsuffizienz (LI) mit relev. erhöhtem Blutungsrisiko; leichte LI in Komb. mit Koagulopathie, dialysepfl. Niereninsuffizienz (NI), akute gastrointestinale (GI) Ulzera oder GI ulzerative Erkrankungen, Schwangerschaft, Stillzeit. W: Komedikation (siehe «IA»); <18 Jahre; künstl. Herzklappen; d. Hämostase beeinfl. Arzneimittel. VM: NI (Krea-Cl 15–29 ml/min) od. NI in Komb. mit Arzneimitteln, die den Xarelto®-Plasmaspiegel erhöhen, erhöhtes Risiko unkontrollierter Blutungen und
hämorrhag. Diathese, kurz zurückliegender hämorrhag. Schlaganfall, intrakran. o. intrazerebr. Hämorrhagie, kürzlich aufgetretene GI Ulzera/ulzerative Erkrankungen, schwere unkontrollierte Hypertonie, vask. Retinopathie, intraspinale o. intrazerebr. Gefässanomalien, kurz zurückliegende Hirn-, Spinal-, Augen-OP, Bronchiektasie oder pulmonale Blutung in der Anamnese, Spinalanästhesie und -punktion, mind. 24 Stunden vor invasiven Verfahren/chirurgischen Eingriffen absetzen, gleichzeitige Gabe von d. Hämostase beeinfl. Arzneimitteln.
Häufige UAW: Blutungen, Anämie, Schwindel, Kopfschmerz, Augenblutungen, Hämatome, Epistaxis, Hämoptysis, Nausea, Obstipation, Durchfall, Leberenzymerhöhungen (ASAT,
ALAT), Pruritus, Rash, Schmerzen i. d. Extrem., Fieber, periph. Ödem, Asthenie. IA: Starke CYP 3A4 + P-gp-Inhib. (Ritonavir, Ketoconazol), starke CYP 3A4 + P-gp-Induk. (Rifampicin,
Carbamazepin, Phenobarbital, Johanniskraut), d. Hämostase beeinfl. Arzneimittel. Stand d. Information: Feb. 2014. Packg.: 10 mg à 10 und 30; 15 mg und 20 mg à je 14, 28 o. 98
Filmtabl.; jew. Klinikpackung 10x 1 Filmtabl. (B), kassenzulässig. Für weitere Informationen siehe www.swissmedicinfo.ch. Vertrieb: Bayer (Schweiz) AG, Bayer Healthcare, Grubenstr. 6,
8045 Zürich. L.CH.HC.04.2014.0413-DE/FR/IT
L.CH.HC.08.2014.0456-DE/FR/IT
Antikoagulation – so einfach wie noch nie*
Referenzen: 1. Fachinformation Xarelto® Schweiz (Stand Februar 2014). 2. Eriksson BI et al. Oral Rivaroxaban for the Prevention of Symptomatic Venous Thromboembolism after
Elective Hip and Knee Replacement; J Bone Joint Surg 2009; 91-B:636-44. 3. Prins et al. Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic Venous Thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013; 11:21. 4. Bauersachs et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. 5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011;
365:883–91.
Lipid Management
Coffee
Parallel Sessions
Paul Lichtlen Lecture
Atherosclerosis, Genetics
10:00-10:30 Coffee
10:30-11:30
Hypertension
08:00-09:30
09:30-10:00
10:00-11:30
17:00-17:15 Poster Award
17:15-17:45 Davos Lecture
Parallel Sessions
1.Acute Coronary Syndromes
2.Mitral Valve Regurgitation
Parallel Sessions
Meet the Expert
Hands-on Session
Poster Session
Parallel Sessions
1. Ventricular Arrhythmias
2. Pulmonary Hypertension
Dinner Buffet
Satellite Symposia
Biotronik
AstraZeneca
Parallel Sessions
Clinical Decision Seminar
ICD and CRT: Troubleshooting
Cardiovascular Imaging
Parallel Sessions
Meet the Expert
Hands-on Session
Poster Session
1. Sports Cardiology
2. Risk Factors and Prevention
Dinner Buffet
Satellite Symposium
Bayer Healthcare
Amgen
Clinical Decision Seminar
Echo Pearls
16:30-17:30
17:30-18:00
18:00-19:15
19:20-20:15
15:30-17:00
Acute and Advanced
Heart Failure
Parallel Sessions
Meet the Expert
Hands-on Session
Coffee
Coffee
15:30-16:30
Diagnosing congenital heart disease
Parallel Sessions
Clinical Decision Seminar
Difficult ECG Interpretations
Satellite Symposium
Daiichi Sankyo / Lilly
Dinner Buffet
Coffee
17:45-18:00
Closing Remarks
Coffee
13:30-14:30
Heart Failure II
14:30-15:15
Meet the Expert
15:00-15:30
Percutaneous Interventions
Thrombosis and Pulmonary
Embolism
Diabetes, Obesity
Lunch/Satellite Symposium
Novartis
13:30-15:00
Lunch/Satellite Symposium
Daiichi Sankyo
Heart Failure I
Coffee
Aortic Valve Disease
Thursday, 12 February
Lunch/ Satellite Symposium
Servier
Lunch/Satellite Symposium
Sanofi
Daiichi-Sankyo
Cardiomyopathies, SCD
Coffee
Atrial Fibrillation
Wednesday, 11 February
12:00-13:15
1. Stable Coronary Artery Disease
2. Cardiac Imaging
Tuesday, 10 February
Monday, 09 February
7
Programme Overview
8
Teaching Faculty
International Faculty
Atar Dan, Oslo, NO
Bax Jeroen J. Leiden, NL
Bounameaux Henri, Geneva, CH
Calkins Hugh, Baltimore, US
Camici Paolo G., Milan, IT
Camm John A., London, GB
Catapano Alberico L., Milan, IT
Chapman John, Paris, FR
Corrado Domenico, Padova, IT
Cosentino Francesco, Stockholm, SE
Crea Filippo, Rome, IT
Deanfield John E., London, GB
Elliott Perry, London, GB
Falk Volkmar, Berlin, DE
Filippatos Gerasimos, Athens, GR
Gersh Bernard, Rochester, US
Gillebert Thierry, Gent BE
Giugliano R.P., Boston , US
Grünig Ekkehard, Heidelberg, DE
Hindricks Gerhard, Leipzig, DE
James Stefan K., Uppsala, SE
Krähenbühl Stephan, Basel, CH
Kucher Nils, Berne, CH
Landmesser Ulf, Berlin, DE
Libby Peter, Boston, US
Mach François, Geneva, CH
Maisano Francesco, Zurich, CH
Meier Bernhard, Berne, CH
Milicic Davor, Zagreb, HR
Müller Christian, Basel, CH
Münzel Thomas, Mainz, DE
Naeije Robert, Brussels, BE
Niebauer Josef, Salzburg, AT
Pfeffer Marc, Boston, US
Pinto Fausto José, Lisboa, PT
Pitt Bertram, Ann Arbor, US
Pitt Geoffrey S., Durham, US
Pocock Stuart, London, UK
Ponikowski Piotr, Wroclaw, PL
Serruys Patrick W., Rotterdam, NL
Sharma Sanjay, London, GB
Smiseth Otto A., Oslo,NO
Solomon Scott David, Boston, US
Storey Robert F., Sheffield, UK
Swedberg Karl B., Göteborg, SE
Vachiery Jean-Luc, Brussels, BE
Vahanian Alec , Paris, FR
Wijns William, Aalst ,BE
Windecker Stephan, Bern CH
Wood David, London, GB
Yusuf Salim, Hamilton, CA
Local Zurich Faculty
Binder Ronald
Brunckhorst Corinna
Duru Firat
Enseleit Frank
Flammer Andreas
Frank Michelle
Gämperli Oliver
Greutmann Matthias
Gruner Christiane
Haegeli Laurent
Klingenberg Roland
Lehmann Roger
Maier Willibald
Manka Robert
Matter Christian
Nietlispach Fabian
Ruschitzka Frank
Schmied Christian
Steffel Jan
Sudano Isabella
Tanner Felix C.
Templin Christian
Ulrich Silvia
Status October 2014
Satellite Symposia
Monday, 9 February 2015, 12:00 –13:15
Hypertension and the Vascular Continuum
Organised together with Servier
Monday, 9 February 2015, 18:00–19:15
Atrial Fibrillation, Cardioversion and NOACs:
Practical Considerations and Patient Management
Organised together with Bayer Healthcare
Monday, 9 February 2015, 18:00 –19:15
Let’s Meet PCSK9 Inhibition – Let’s Meet LDL Targets
Organised together with Amgen
Tuesday, 10 February 2015, 12:00–13:15
Novel Therapeutic Approach for the Management of Dyslipidemia
Organised together with Sanofi
Tuesday, 10 February 2015, 12:00–13:15
Individualised Therapy of Hypertension for Young and Older Patients
Organised together with Daiichi-Sankyo
Tuesday, 10 February 2015, 18:00 –19:15
From Acute Care to Long Term Benefit in ACS
Organised together with AstraZeneca
Tuesday, 10 February 2015, 18:00–19:15
Modern Management of Cardiac Device Patients
Organised together with Biotronik
Wednesday, 11 February 2015, 12:00–13:15
Meeting the Challenges in Atrial Fibrillation Management
Organised together with Daiichi Sankyo
Wednesday, 11 February 2015, 18:00 –19:15
Five Years Prasugrel: What Have we Learned and Where Are we Going ?
Organised together with Daiichi Sankyo/Eli Lilly
9
Thursday, 12 February 2015, 12:00 –13:15
Novel Therapies for Chronic Heart Failure – an Expert Panel Discussion
Organised together with Novartis Pharma
Special Sessions
Echo Hands-on Sessions
Special TEE echo tutorial sessions provide participants with an opportunity for hands-on learning with experienced echocardiographers. Tutorials take place in a state-of-the-art setting
with attendance limited to 4 participants to offer an intimate and interactive hands-on learning
experience with «Heartworks Phantoms» and simulation of different structural heart disease.
The sessions will be held on Tuesday afternoon, 10 February 2015 from 13:30 to 18:00. Duration of a tutorial is 60 minutes. A total of 8 tutorials will be held. The number of participants is
limited to 32 people.
Extra cost: CHF 80.-. The sessions can be booked on the registration form on our website.
Tutorial slots will be assigned to the first 32 applications. Upon registration no refund of costs
will be possible.
Moderated Poster Sessions
Submitted abstracts which are accepted for poster exhibition will be displayed in the Foyer from
Monday to Wednesday. During a guided poster viewing the presenters will summarize their research within 5 minutes. They then will address questions from chairpersons and audience. The
chairpersons will identify the best moderated posters from each session and a jury will select the
best three posters of all sessions for awards of CHF 3000.-, 2000.- and 1000.
Accreditation
Cardiology Update is recognised by the following medical societies and associations as accredited continuing education:
EBAC, European Board for Accreditation in Cardiology (24 CME credits)
EACCME, European Accreditation Council for Continuing Medical Education (24 CME credits)
Swiss Society of Cardiology (30 CME credits category 1A)
Swiss Society of Internal Medicine (30 CME credits category 1A)
German Cardiac Society (30 CME credits)
10
German Cardiac Society
General Information
Venue
Congress Center, Davos, Switzerland (www.davoscongress.ch)
Registration
Registrations can be made exclusively online on our website (www.cardiologyupdate.ch)
Registration fee before 20 December 2014, CHF (Swiss Francs) 980.00
Registration fee after 20 December 2014, CHF 1100.00
On-site Registration: CHF 1200.00
Registration fee for fellows and nurses (identification requested): CHF 490.00
Single day tickets Monday – Thursday: CHF 300.00
Registration will be confirmed upon receipt of payment.
Echo Hands-on Session: CHF 80.00 (limited to 32 participants)
Group Registration
For group registration a minimum of 10 participants is required. Please contact Mrs. Esther Willi
(esther.willi@usz.ch) to obtain further information. Congress documents and bags can be collected as early pick-up upon request.
Modification & Cancellation
All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to Davos
Congress. For each modification requested by the participant, CHF 50.00 will be charged for
administrative costs. In case of cancellation up to 14 January 2015, deposits will be refunded
less 35% for administrative costs. After this date, no refund will be possible.
Methods of payment
The fees should be paid in Swiss Francs (CHF) and settled by the following credit cards:
VISA or Eurocard/Mastercard.
Contact: Davos Congress, Mrs. Sandra Sutter (cardio@davos.ch ).
Hotel Reservation
Hotel rooms are available at a special convention rate. Reservations can be made on our website
(www.cardiologyupdate.ch) or at Davos Congress, Mrs. Sandra Sutter (cardio@davos.ch).
11
Abstracts
Abstracts for the Poster Session can be submitted exclusively on our website (www.cardiologyupdate.ch). An Abstract Booklet will be published.
Deadline for submission: 19 December 2014, Midday CET.
Registration Desk
The registration desk and congress secretariat is located in the foyer of the Congress Center.
Opening hours:
Sunday, 8 February 2015
16:00–18:30
Monday-Wednesday, 9-11 February 2015
07:30–12:00 14:00–19:00
Thursday, February 12, 2015
08:00–12:00 14:00–18:00
Travel Information
As official carrier to Cardiology Update 2015 in Davos Swiss International Air Lines offers you
the best booking flexibility together with Swiss product and service quality, all at a significantly
discounted price. As the national airline of Switzerland we offer event participants a reduction
of up to 10% off regular fares. Your stay in Switzerland begins the moment you board one of
our aircraft.
Special congress fares are indicated with a „C“ and make it possible for you to rebook flexibly
or cancel if necessary. Reductions depend on the fare type, routing and availability and are valid
on the full SWISS network for flights to Switzerland, including flights operated by one of our
partner airlines with an LX flight number. These fares are bookable with immediate effect for the
travel period 14 days before and after the event.
To take advantage of this offer, book simply and conveniently on swiss.com via the following
link:
www.swiss.com/event
Please enter your email address and the event code that will be provided with your registration
confirmation.
SWISS is already looking forward to pampering you with typical Swiss hospitality on board.
12
Journey from Zurich Airport to Davos
The closest airport to Davos is Zurich Airport. Davos can be reached from the airport by train.
Trains run on a half hourly basis. The duration of the journey is approximately 3 hours.
Timetables of the Swiss railroad network can be found on: www.sbb.ch
About the Zurich Heart House
A Foundation associated with the University of Zurich and
the University Hospital Zurich
The Zurich Heart House (ZHH) is a place for the exchange of knowledge and cooperation between researchers, clinicians and practicing physicians. Founded in the year 2009 and conceived
as a small sister of the European Heart House the ZHH focuses on the field of cardiovascular
medicine and promotes research projects and educational activities that receive worldwide attention.
The ZHH unifies the Foundation for Cardiovascular Research which is its legal entity together
with its Education Center and the editorial office of two scientific journals, The “European Heart
Journal” and “Cardiovascular Medicine”. Altogether the ZHH offers jobs to 15 employees and
in addition supports about 40 scientists, fellows and researchers employed by the University of
Zurich. The director of the Zurich Heart House is Ruth Amstein, Ph.D. with a background in cardiovascular research and working experience in pharmaceutical industry and university-industry
partnerships.
13
Your team at Cardiology Update (from left)
Dr. Ruth Amstein, Esther Willi, Valérie Streichenberg, Kathrin Reber
Registration, Organisation
Registration
Registrations have to be submitted online: www.cardiologyupdate.ch
Davos Destinations-Organisation
Davos Congress
Mrs. Sandra Sutter
Tourismus- und Sportzentrum
CH-7270 Davos Platz, Switzerland
Email: cardio@davos.ch
Phone +41 (0) 81 415 21 63, Fax +41 (0) 81 415 21 69
Organisation
Zurich Heart House
Foundation for Cardiovascular Research
Ruth Amstein, Ph.D., (ruth.amstein@usz.ch)
Esther Willi (esther.willi@usz.ch)
Kathrin Reber (kathrin.reber@usz.ch)
Valérie Streichenberg (valerie.streichenberg@usz.ch )
Moussonstrasse 4, CH-8091 Zurich, Switzerland
Phone +41 (0) 44 250 40 83, Fax +41 (0) 44 250 40 90
14
www.cardiologyupdate.ch
Platinum Sponsors
Gold Plus Sponsors
Gold Sponsors
Actelion Pharma Schweiz AG
Boehringer Ingelheim (Schweiz) GmbH
A. Menarini AG
The Medicines Company (Schweiz) GmbH
Co-Sponsor
16
Pfizer AG
www.cardiologyupdate.ch
Title Page: CT-Image by Philipp A. Kaufmann, M.D.
University Hospital Zurich
© ZHH 2014
Silver Sponsors
Autor
Document
Kategorie
Uncategorized
Seitenansichten
20
Dateigröße
1 413 KB
Tags
1/--Seiten
melden